oper leverag room run
pre-announce link today report ad color
sale yoy vs estimate led novaseq shipment
high sequenc consum yoy sale sequenc
instrument y/i vs estimate array strong
yoy led dtc genom demand adj gm yoy
estimate favor mix adj opm yoy vs
est non-gaap ep vs our/street est
placement expect
custom shift hiseq instrument placement mute
expect benchtop portfolio larg line stronger nextseq
hiseq consum pull-through well higher servic revenu drove
upsid see placement roughli line quarterli run-
rate seen estimate total instrument sale increas yoy
see upsid benchtop forecast shift focu post launch
said consum major driver revenu growth estimate
yoy instal base ramp nextseq pull-through continu outperform
off-set lower hiseq famili pull addit tailwind includ robust array sale
benefit consum genom growth expans grail/helix busi
guid unchang see upsid rais po
management reiter prior guid revenu growth adj ep
howev view guid conserv given continu runway novaseq
placement potenti increment driver strong array busi new system
part portfolio grail/helix etc remind initi revenu guid
growth gradual rais finish year
believ similar prudent conservat could play expect
sale yoy ep
reiter buy rate novaseq live high expect demand
sequenc remain robust base increment higher forecast dcf base
po wacc termin growth rate increas
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart san diego california
consum servic genet analysi
compani proprietari product servic
use research broad spectrum
scientif activ gain greater understand
genet variat biolog function
tool play import role
develop creation molecular test
posit prospect due wide
adopt compani innov genet
analysi tool strong competit posit
impress forward-look product market
strategi although macro competit risk
remain believ compani recent
launch near-term pipelin help
remain forefront
price object base dcf analysi assum wacc
approxim termin growth rate po approxim
revenu estim roughli ep estim consid
justifi given attract long-term outlook genom market compani
technolog leadership new product cycl increas penetr fast-
grow clinic appli market
downsid risk po weaker-than-expect academ fund lower
consum pull-through competit within genet analysi market regulatori
reimburs uncertainti clinic sequenc market acquisit integr
issu recent manag chang slower-than-expect uptak new product
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
